An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Oval tablets containing 375 mg of telaprevir for oral administration.

Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.

Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.

Tablets containing 200 mg RBV for oral administration.

Capsules containing 200 mg RBV for oral administration.